Zacks Investment Research
19 Nov 2026, 15:51 UTC · 3h ago
ImmuCell Q3 Earnings Rebound as Sales Surge and Margins Expand Y/Y
Impact · against what's priced in
ImmuCell's Q3 results show a successful transition to profitability driven by strong sales growth and margin expansion. While the figures are positive, the immediate market reaction of a 10.4% price increase suggests these gains are being rapidly absorbed by the valuation.
- ICCC+0.40
No priced-in read yet
- In context
The company reversed a prior-year loss to achieve earnings of 10 cents per share, supported by a 46% year-over-year increase in product sales to $8.04 million.
Read from the article alone

Top 1 mover · tap to explore




